- GTx (GTXI) jumps out the blocks in response to its announcement that enobosarm has achieved both stage 1 and stage 2 primary endpoints its its ongoing Phase 2 clinical trial in women with advanced estrogen receptor-positive (ER+), androgen receptor-positive (AR+) breast cancer. The company will release top-line data next month with complete results to follow in mid-2017.
- Enobosarm is a non-steroidal androgen receptor agonist. It may offer an alternative hormonal approach for the treatment of endocrine-sensitive advanced breast cancer prior to chemotherapy.
- Shares are up 4% on increased volume.
- Previously: Stage 1 milestone met in GTx's mid-stage study of lead product candidate in certain type of breast cancer, trial to advance to Stage 2 (Nov. 16)
GTX's enobosarm successful in mid-stage breast cancer study; shares up 4%
Recommended For You
About ONCT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ONCT | - | - |
Oncternal Therapeutics, Inc. |